Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention
Status:
Completed
Trial end date:
2019-09-17
Target enrollment:
Participant gender:
Summary
The object of the study is to determine whether different doses of PZ-128, when added to
standard medical care in persons undergoing cardiac catheterization/percutaneous coronary
intervention, will increase the risk of bleeding.
A secondary objective is to determine whether patients treated with PZ-128 have fewer cardiac
events such as heart attack, bypass surgery or stroke compared with those persons treated
with the standard of care.
Phase:
Phase 2
Details
Lead Sponsor:
Tufts Medical Center
Collaborators:
Inova Fairfax Hospital National Heart, Lung, and Blood Institute (NHLBI) RTI International University of Massachusetts, Worcester